Palisade Bio Aktie Logo
US6963894026

Palisade Bio Aktie

Ins Portfolio
Kostengünstig und breit gestreut in Europa investieren. Jetzt entdecken
Anzeige

Kurse werden geladen...

Prognose

Das durchschnittliche Kursziel der Analysten beträgt +1,29(+101,56%). Der Median liegt bei +1,29(+101,56%).

Kaufen
  3
Halten
  0
Verkaufen
  0

Scoring-Modelle

Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.

News


  • Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn's Disease and Ulcerative Colitis

    Study met its primary endpoints of safety, tolerability, and pharmacokinetics (PK)  No serious adverse events (SAEs) or treatment-emergent adverse events (TEAEs) related to laboratory values or EKGs observed across SAD/MAD cohorts Management releases a “What This Means” segment discussing the topline Phase 1a data; Access here Carlsbad, CA, May 27, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced positive topline results from its completed Phase 1 studies of PALI-2108, a novel, locally-activated, terminal ileum and colon-targeted phosphodiesterase-4 B/D (PDE4 B/D) inhibitor being developed for fibrostenotic Crohn's disease (FSCD) and moderate to severe ulcerative colitis (UC). Additionally, the Company announced the release of a Virtual Investor “What This Means” segment to discuss the topline data, which is now available here.» Mehr auf globenewswire.com


  • Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases

    Two posters presented at Digestive Disease Week (DDW) 2025 Preclinical results indicate that PALI-2108 effectively modulates inflammatory pathways in the colon, promoting a favorable immune response Company advancing Phase 1a/b study of PALI-2108 and has demonstrated a favorable safety profile in single-ascending-dose cohorts Carlsbad, CA, May 06, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced the presentation of positive preclinical data from PALI-2108, an orally administered, colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug in development for patients with ulcerative colitis (UC). The presented data highlighted the efficacy and safety profile of PALI-2108 in a mouse model of colitis, with a particular focus on its impact on PDE4B expression, cAMP levels, and TNF-α suppression as well as predicting efficacious PALI-0008 levels in patients.» Mehr auf globenewswire.com


  • Palisade Bio's AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit

    Carlsbad, CA, May 01, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it has been selected to give an oral presentation at the 3 rd Annual Precision Medicine in Inflammatory Bowel Disease Summit being held May 13–15, 2025 in Boston, MA.» Mehr auf globenewswire.com

Dividenden

Alle Kennzahlen
In 2002 hat Palisade Bio Aktie +291.537,26 Dividende ausgeschüttet. Die letzte Dividende wurde im März 2002 gezahlt.

Unternehmenszahlen

Im letzten Quartal hatte Palisade Bio Aktie einen Umsatz von 0,00 und ein Nettoeinkommen von 2,06 Mio
(EUR)März 2025
YOY
Umsatz0,00-
Bruttoeinkommen0,00100,00%
Nettoeinkommen2,06 Mio36,92%
EBITDA2,06 Mio36,95%

Fundamentaldaten

MetrikWert
Marktkapitalisierung
+3,06 Mio
Anzahl Aktien
4,80 Mio
52 Wochen-Hoch/Tief
+4,22 - +0,52
DividendenNein
Beta
1,34
KGV (PE Ratio)
0,27
KGWV (PEG Ratio)
0,05
KBV (PB Ratio)
+0,67
KUV (PS Ratio)
0,00

Unternehmensprofil

Name
Palisade Bio Aktie
CEO
J. D. Finley
Mitarbeiter8
🍪

Parqet nutzt Cookies.Erfahre Mehr